Erwinaze

[Jimin Pharmaceutical Guide] Erwinaze is used to treat a rare acute lymphoblastic leukemia (ALL). There are about 6,000 new cases of this disease in the United States each year. It usually occurs in children and adolescents, and the incidence in adults is relatively low. Acute lymphoblastic leukemia is the most common type of childhood tumor. The cause is still to be confirmed and cannot be prevented.

This product is an injection, each bottle contains 10,000 international units. The recommended dose is 25,000 international units, intramuscular injection, 3 times a week.

Erwinase was developed by Jazz Pharmaceuticals in the United States and approved by the US FDA in 2014 for the treatment of acute lymphoblastic leukemia. It is an orphan drug with a small audience.